Mesalazine

Generic Name
Mesalazine
Brand Names
Apriso, Asacol, Canasa, Delzicol, Lialda, Mezavant, Pentasa, Rowasa, Salofalk, Zaldyon
Drug Type
Small Molecule
Chemical Formula
C7H7NO3
CAS Number
89-57-6
Unique Ingredient Identifier
4Q81I59GXC
Background

An anti-inflammatory agent, structurally related to the salicylates and non-steroidal anti-inflammatory drugs like acetylsalicylic acid, which is active in inflammatory bowel disease . Although demonstrably effective in treating and maintaining remission for ulcerative colitis, mesalazine has historically faced a number of issues regarding its lack of stabil...

Indication

适用于溃疡性结肠炎和克罗恩病（Crohn病）。

Associated Conditions
Acute Ulcerative Colitis, Crohn's Disease Relapse, Crohn's Ileocolitis, Mild to Moderate Ulcerative Colitis, Proctitis, Proctitis, Ulcerative, Proctosigmoiditis, Ulcerative Colitis in Remission, Mild Ulcerative Colitis, Mild to moderate distal ulcerative colitis, Moderate Ulcerative colitis
Associated Therapies
-
Clinical Trials
Related News

Therapeutic Effect of Methalazine on 27 Cases of Suppurative Hidradenitis

Completed
Conditions
Hidradenitis Suppurativa
First Posted Date
2024-08-23
Last Posted Date
2024-08-23
Lead Sponsor
The First Affiliated Hospital with Nanjing Medical University
Target Recruit Count
27
Registration Number
NCT06568224
Locations
🇨🇳

Jiangsu Provincial People's Hospital, Nanjing, Nanjing, China

Clinical Study to Evaluate the Possible Efficacy and Safety of Febuxostat in Patients With Ulcerative Colitis Treated With Mesalamine

Early Phase 1
Not yet recruiting
Conditions
Ulcerative Colitis
Interventions
Drug: Mesalamine
Drug: Febuxostat
First Posted Date
2024-07-29
Last Posted Date
2024-07-29
Lead Sponsor
Tanta University
Target Recruit Count
46
Registration Number
NCT06525974

Minocyclin in Ulcerative Colitis as Added on Therapy

Phase 2
Recruiting
Conditions
Inflammatory Bowel Diseases
Interventions
Drug: Mesalazine
Drug: Minocycline
First Posted Date
2024-01-11
Last Posted Date
2024-01-30
Lead Sponsor
Mostafa Bahaa
Target Recruit Count
46
Registration Number
NCT06201793
Locations
🇪🇬

Faculty of Medicine, Mansoura University, Mansoura, Egypt

Phase III Multicentre Trial of Oral Mesalazine in Patients With Mild to Moderate Ulcerative Colitis.

Phase 3
Not yet recruiting
Conditions
Colitis, Ulcerative
Interventions
Drug: Mesalazine
First Posted Date
2023-12-19
Last Posted Date
2023-12-19
Lead Sponsor
Faes Farma, S.A.
Target Recruit Count
376
Registration Number
NCT06176560

ChAracterizing the Remission Status in Patients With Ulcerative Colitis Treated by 5-ASA

Phase 4
Completed
Conditions
Ulcerative Colitis
Interventions
Drug: 5-ASA
First Posted Date
2023-08-15
Last Posted Date
2024-03-21
Lead Sponsor
Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW
Target Recruit Count
200
Registration Number
NCT05992142
Locations
🇧🇪

AZ Voorkempen Malle, Malle, Belgium

🇧🇪

Hôpital Erasme, Bruxelles, Belgium

🇧🇪

AZ Sint-Lucas Gent, Gent, Belgium

and more 13 locations

Clinical Study to Evaluate the Possible Efficacy of Nifuroxazide in Patient With Ulcerative Colitis

First Posted Date
2023-08-14
Last Posted Date
2023-08-23
Lead Sponsor
Mostafa Bahaa
Target Recruit Count
50
Registration Number
NCT05988528
Locations
🇪🇬

Tanta University, Tanta, Egypt

Activation of Autophagy and Suppression of Apoptosis by Dapagliflozin Attenuates Inflammatory Bowel Disease

First Posted Date
2023-08-14
Last Posted Date
2023-09-06
Lead Sponsor
Mostafa Bahaa
Target Recruit Count
50
Registration Number
NCT05986136
Locations
🇪🇬

Faculty of Medicine, Mansoura University, Mansoura, Egypt

Repurposing Fenofibrate in Modulating mTOR/NLRP3 Inflammasome in Patients With Ulcerative Colitis

Phase 2
Recruiting
Conditions
Inflammatory Bowel Diseases
Interventions
Drug: Mesalamine
Drug: Fenofibrate
First Posted Date
2023-03-23
Last Posted Date
2024-04-10
Lead Sponsor
Tanta University
Target Recruit Count
60
Registration Number
NCT05781698
Locations
🇪🇬

Faculty of Medicine, Menoufia University, Tanta, Shebeen El-Kom, Egypt

Fenofibrate in Ulcerative Colitis

First Posted Date
2023-03-03
Last Posted Date
2024-04-10
Lead Sponsor
Tanta University
Target Recruit Count
60
Registration Number
NCT05753267
Locations
🇪🇬

Tanta Unuversity, Tanta, Egypt

Prophylactic Mesalamine to Prevent Colitis Following Treatment With Ipilimumab/Nivolumab (Ipi/Nivo)

First Posted Date
2022-12-23
Last Posted Date
2024-06-12
Lead Sponsor
AHS Cancer Control Alberta
Target Recruit Count
20
Registration Number
NCT05663775
Locations
🇨🇦

Cross Cancer Institute, Edmonton, Alberta, Canada

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy